Skip to main content
. 2017 Feb 2;8(9):15827–15837. doi: 10.18632/oncotarget.15015

Figure 1. IDH1 mutation promotes resistance to TMZ by D2HG production.

Figure 1

A. Western blot confirming expression of exogenous HA-IDH1 (red) and endogenous IDH1 (green). B. Clonogenic survival of empty vector control, IDH1 WT, and IDH1 mutant astrocytes after treatment with 100μM TMZ. C. MGMT expression was not detectable by Western blot in astrocytes regardless of IDH1 status. MCF7 cells were used as a positive control. D. Impact of mutant IDH1 on cell cycle profiles in response to TMZ treatment. Yellow boxes indicate>30% of cells in G2/M. E. Clonogenic survival of parental astrocytes (top) and IDH1 mutant astrocytes (bottom) cultured with or without 5mM D2HG and treated with TMZ. There was a statistically significant interaction between D2HG and TMZ treatments in the NHA (P=0.02) but not in IDH1 mutant astrocytes. Error bars represent SEM. P<0.05 (*); P<0.01 (**).